Category: Wall Street Beat
Here's a look at some of the top Wall Street stories for medical device companies this week: Medtronic updates on $43B Covidien deal financing; Boston Scientific, Bard CEOs cool on consolidation; Nevro sets range for IPO of up to $106m; Alere to sell Alere Health unit to Optum for $600m; Skyline Medical conducts 1-for-75 reverse stock split
Breast implant maker Sientra prices its initial public offering at $15 per share.
Breast implant maker Sientra priced its initial public offering at $15 per share, saying it plans to issue 5 million shares for a total of $75 million.
Sientra, which also has designed implants for the buttocks, calf, pectoral region and face, has backers including Abingworth Bioventures, OrbiMed and Clarus Lifesciences.
Alere says it plans to sell its health-management unit to Optum for $600 million in cash in order to focus on its core rapid diagnostics business.
Alere agreed to sell Alere Health, its health-management unit, to health-services provider Optum for $600 million in cash in order to focus on its core rapid diagnostics business.
Nevro Corp. sets the per-share price range for its pending initial public offering, which would raise more than $106 million at the high end.
Nevro Corp. set the price range for its forthcoming initial public offering, which would raise $106.3 million at the high end of the range.
Menlo Park, Calif.-based Nevro plans to trade on the NASDAQ exchange under the symbol NVRO, according to a regulatory filing.
Skyline Medical conducts a 1-for-75 reverse stock split, reducing the number of outstanding shares to approximately 3 million.
Valeant Pharmaceuticals says it's ready to up the ante in its hostile takeover bid for Allergan.
Salesforce is reportedly ramping up to enter the healthcare market in a big way.